Plain-English translation of NCT06356571 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for multiple myeloma, a type of blood cancer that has stopped responding to previous therapies. The study combines isatuximab—a newer medication given as an injection under the skin using a small wearable device—with two established cancer drugs given intravenously () and by mouth or IV (). Researchers want to see if this three-drug combination can help control the cancer and improve outcomes for patients whose disease has become resistant to standard treatments.
Multiple myeloma often stops responding to initial treatments, leaving patients with limited options. This medication represents a newer approach to attacking the cancer cells, and researchers believe combining it with two proven drugs may offer better results for patients in this difficult situation.
You would visit the study site regularly over a 12-month treatment period, divided into four-week cycles. During Cycle 1, you would receive the injection under your skin on four days and two intravenous infusions on different days, along with oral or IV . In later cycles, the injection schedule eases to twice per cycle while the IV drug continues on three days per cycle. The study includes a screening visit, regular treatment visits, and a follow-up visit about 30 days after your last treatment dose.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States